Physician profile
Michael G Goldmeier
NPI 1265439400
$1,219.46
in general payments reported to CMS, 2019-2025
12 companies · $78.03 in 2025
The $78.03 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $55.41 · 2021: $131 · 2022: $289 · 2023: $226 · 2024: $79.83 · 2025: $78.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $384.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $476.38 | 2019-2025 | |
| Boston Scientific Corporation | $144.55 | 2019-2023 | Watchman Access System |
| Cardiovascular Systems INC. | $125.00 | 2019 | |
| Medtronic Vascular, INC. | $125.00 | 2019 | |
| Abbott Laboratories | $83.37 | 2020-2022 | |
| Amgen INC. | $68.65 | 2020-2025 | Repatha |
| Pfizer INC. | $50.71 | 2020-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.47 | 2019-2025 | Lifevest |
| Abiomed | $49.38 | 2024 | Impella |
| Shockwave Medical, INC | $16.76 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $16.45 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $13.74 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Goldmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.